Prediction of neo-adjuvant chemotherapy response in bladder cancer: the impact of clinical parameters and routine biomarkers

References

• Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19(3):666–675.
   PubMed Web of Science ®Google Scholar
• Russell B, Sherif A, Haggstrom C, et al. Neoadjuvant chemotherapy for muscle invasive bladder cancer: a nationwide investigation on survival, scand. J. Urol. 2019;53(4):206–212.
   Web of Science ®Google Scholar
• Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and Meta-Analysis. Lancet. 2003;361:1927–1934.
   PubMed Web of Science ®Google Scholar
• Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and Meta-Analysis. J Urol. 2004;171(2 Pt 1):561–569.
   PubMed Web of Science ®Google Scholar
• Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for Muscle-Invasive urothelial bladder cancer. Eur Urol. 2012;61(6):1229–1238.
   PubMed Web of Science ®Google Scholar
• Buisan O, Orsola A, Areal J, et al. Low pretreatment neutrophil-to-Lymphocyte ratio predicts for good outcomes in patients receiving neoadjuvant chemotherapy before radical cystectomy for muscle invasive bladder cancer. Clin Genitourin Cancer. 2017;15(1):145–151.e2.
   PubMed Web of Science ®Google Scholar
• Groenendijk FH, de Jong J, Fransen van de Putte EE, et al. ERBB2 mutations characterize a subgroup of Muscle-Invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol. 2016;69(3):384–388.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Tokunaga H, Zhou J, et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004;22(6):1014–1024.
   PubMed Web of Science ®Google Scholar
• Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331(19):1259–1264.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Hoffman-Censits JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for Muscle-Invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014;32(18):1895–1901.
   PubMed Web of Science ®Google Scholar
• Sarkis AS, Bajorin DF, Reuter VE, et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol. 1995;13(6):1384–1390.
   PubMed Web of Science ®Google Scholar
• Maluf FC, Cordon-Cardo C, Verbel DA, et al. Assessing interactions between mdm-2, p53, and bcl-2 as prognostic variables in Muscle-Invasive bladder cancer treated with Neo-Adjuvant chemotherapy followed by locoregional surgical treatment. Ann Oncol. 2006;17(11):1677–1686.
   PubMed Web of Science ®Google Scholar
• Stadler WM, Lerner SP, Groshen S, et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011;29(25):3443–3449.
   PubMed Web of Science ®Google Scholar
• Mellon K, Neal DE, Robinson MC, et al. Cell cycling in bladder carcinoma determined by monoclonal antibody Ki67. Br J Urol. 1990;66(3):281–285.
   PubMedGoogle Scholar
• Margulis V, Shariat SF, Ashfaq R, et al. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for Organ-Confined disease. Clin Cancer Res. 2006;12(24):7369–7373.
   PubMed Web of Science ®Google Scholar
• Grossman HB, Tangen CM, Cordon-Cardo C, et al. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a southwest oncology group study. Oncol Rep. 2006;16:807–810.
   PubMed Web of Science ®Google Scholar
• King CR, Kraus MH, Aaronson SA. Amplification of a novel V-erbB-related gene in a human mammary carcinoma. Science. 1985;229(4717):974–976.
   PubMed Web of Science ®Google Scholar
• Chow NH, Liu HS, Yang HB, et al. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. an immunohistochemical study. Virchows Arch. 1997;430(6):461–466.
   PubMed Web of Science ®Google Scholar
• Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using Formalin-Fixed, Paraffin-Embedded archival tissues. Hum Pathol. 2012;43(10):1590–1595.
   PubMed Web of Science ®Google Scholar
• Kolla SB, Seth A, Singh MK, et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol. 2008;40(2):321–327.
   PubMed Web of Science ®Google Scholar
• Krüger S, Weitsch G, Büttner H, et al. Overexpression of C-erbB-2 oncoprotein in Muscle-Invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol. 2002;21(5):981–987.
   PubMed Web of Science ®Google Scholar
• Kramer C, Klasmeyer K, Bojar H, et al. Heparin-Binding epidermal growth Factor-Like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 2007;109(10):2016–2024.
   PubMed Web of Science ®Google Scholar
• Peyton CC, Tang D, Reich RR, et al. Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for Muscle-Invasive bladder cancer. JAMA Oncol. 2018;4(11):1535–1542.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Pal SK, Chowdhury S, et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for Muscle-Invasive bladder cancer. Cancer. 2015;121(15):2586–2593.
   PubMed Web of Science ®Google Scholar
• Radkiewicz C, Edgren G, Johansson ALV, et al. Sex differences in urothelial bladder cancer survival. Clin Genitourin Cancer. 2020;18(1):26–34.e6.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Goldman BH, Speights VO, et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer. 2009;115(18):4104–4109.
   PubMed Web of Science ®Google Scholar
• Bhindi B, Frank I, Mason RJ, et al. Oncologic outcomes for patients with residual cancer at cystectomy following neoadjuvant chemotherapy: a pathologic Stage-Matched analysis. Eur.Urol. 2017;72(5):660–664.
   PubMed Web of Science ®Google Scholar
• Seiler R, Ashab HAD, Erho N, et al. Impact of molecular subtypes in Muscle-Invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy. Eur Urol. 2017;72(4):544–554.
   PubMed Web of Science ®Google Scholar